Description

CORONA Remedies Limited's equity shares admitted to trading on NSE Capital Market segment effective December 15, 2025 following their initial public offering at Rs. 1062 per share.

Summary

National Stock Exchange of India has admitted equity shares of CORONA Remedies Limited to trading on the Capital Market segment effective December 15, 2025. The company completed its initial public offering at Rs. 1062 per share with a face value of Rs. 10. Total issue consists of 61,160,088 equity shares with ISIN INE02ZQ01018 and trading symbol CORONA. The security will participate in the pre-open session for IPO category scrips as per SEBI guidelines.

Key Points

  • Trading Symbol: CORONA, Series: EQ
  • ISIN: INE02ZQ01018
  • Face Value: Rs. 10 per share
  • Issue Price: Rs. 1062 per share
  • Total Securities: 61,160,088 equity shares
  • Market Lot Size: 1 share
  • Effective Trading Date: December 15, 2025
  • Registered Office: CORONA House, C - Mondeal Business Park, S. G. Highway, Thaltej, Ahmedabad - 380059, Gujarat
  • Company Secretary: Ms. Chetna Dharajiya
  • Registrar: Bigshare Services Private Limited, Mumbai
  • Financial Year: April 2025 to March 2026

Regulatory Changes

No regulatory changes. This is a standard IPO listing notification under Regulation 3.1.1 and 2.5.5 of NSE Capital Market Trading Regulations Part A.

Compliance Requirements

  • Members must use designated security code CORONA for trading identification
  • Trading must be conducted in specified lot size of 1 share
  • Security will be part of pre-open session for IPO category as per SEBI circular CIR/MRD/DP/01/2012 & CIR/MRD/DP/02/2012 dated January 20, 2012
  • Lock-in requirements apply to specific share tranches as detailed in Annexure I

Important Dates

  • Circular Date: December 12, 2025
  • Effective Trading Date: December 15, 2025
  • Lock-in Expiry Dates:
    • 12,084,729 shares: June 11, 2026
    • 6,116,010 shares: June 11, 2027
    • 8,564,037 shares: June 11, 2026
    • 6,116,010 shares: June 11, 2027
    • 22,105,251 shares: June 11, 2026
    • 917,402 shares: January 9, 2026
    • 917,402 shares: March 10, 2026
    • 4,339,247 shares: Free (no lock-in)

Impact Assessment

Market Impact: Medium - Addition of new pharmaceutical company stock to NSE trading platform provides investors access to CORONA Remedies Limited. With 61.16 million shares and issue price of Rs. 1062, this represents a sizeable IPO in the pharmaceutical sector.

Operational Impact: Low - Standard listing process with established pre-open session procedures. Trading members can commence trading from December 15, 2025 using standard NSE trading infrastructure.

Investor Impact: Majority of shares (approximately 93%) are under various lock-in periods ranging from January 2026 to June 2027, which may limit immediate float and trading liquidity. Only 4.34 million shares (approximately 7%) are free for immediate trading.

Impact Justification

New IPO listing creates trading opportunity for market participants. Medium impact as it adds a new pharmaceutical company to the exchange but is routine listing activity.